Welcome to Evidence Corner. Here we try to explain the data behind the clinical decisions we make through deep-diving studies that have shaped how we treat patients with liver disease. For each clinical question, we’ve chosen a single study and with our digestible slides, we try to concisely highlight the key aspects of the study.
Can liver transplantation be an effective therapy for intrahepatic cholangiocarcinoma?
Can beta-blockade in patients with clinically significant portal hypertension prevent decompensations? The PREDESCI trial sought out to determine just that!
Effective treatments for NASH have been elusive. Is Semaglutide the answer people have been waiting for?
Is obeticholic acid effective in the treatment of patients with PBC?
In patients with unresectable HCC, what is the best systemic therapy? https://www.nejm.org/doi/full/10.1056/NEJMoa1915745
Ever wondered why we calculate a Lille score in patients being treated for alcohol-associated hepatitis with prednisolone? This is the Evidence Corner for you!
What new condition should be considered and worked up in patients with pediatric acute liver failure of unknown origin?
A review of the study on rifaximin as an adjunctive therapy in treatment of hepatic encephalopathy.
Can polyethylene glycol (PEG) be used to treat hepatic encephalopathy in hospitalized patients?
Ever wondered why we tell people to transfuse to a goal hemoglobin greater than 7? This is the evidence corner for you!
Do you have suggestions for topics within this series? Are you a fellow interested in contributing? Please feel free to reach out via Twitter to the fellow lead or to Liver Fellow Network directly. You can also e-mail us at email@example.com.